Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Adv Healthc Mater ; 13(14): e2302830, 2024 06.
Article in English | MEDLINE | ID: mdl-38366136

ABSTRACT

Tissue engineering holds great promise for regenerative medicine, drug discovery, and as an alternative to animal models. However, as soon as the dimensions of engineered tissue exceed the diffusion limit of oxygen and nutriments, a necrotic core forms leading to irreversible damage. To overcome this constraint, the establishment of a functional perfusion network is essential. In this work, digital light processing bioprinting is used to encapsulate endothelial progenitor cells (EPCs) in 3D light-cured hydrogel scaffolds to guide them toward vascular network formation. In these scaffolds, EPCs proliferate and self-organize within a few days into branched tubular structures with predefined geometry, forming capillary-like vascular tubes or trees of diameters in the range of 10 to 100 µm. Presenting a confluent monolayer wall of cells strongly connect by tight junctions around a central lumen-like space, these structures can be microinjected with a fluorescent dye and are stable for several weeks in vitro. These endothelial structures can be recovered and manipulated in an alginate patch without altering their shape or viability. This approach opens new opportunities for future applications, such as stacking with other cell sheets or multicellular constructs to yield bioengineered tissue with higher complexity and functionality.


Subject(s)
Bioprinting , Endothelial Progenitor Cells , Tissue Engineering , Tissue Scaffolds , Humans , Bioprinting/methods , Tissue Engineering/methods , Tissue Scaffolds/chemistry , Endothelial Progenitor Cells/cytology , Endothelial Progenitor Cells/metabolism , Hydrogels/chemistry , Capillaries/physiology , Alginates/chemistry , Printing, Three-Dimensional
2.
BMC Biol ; 20(1): 218, 2022 10 05.
Article in English | MEDLINE | ID: mdl-36199089

ABSTRACT

BACKGROUND: Perineuronal nets (PNNs) are specialized extracellular matrix structures mainly found around fast-spiking parvalbumin (FS-PV) interneurons. In the adult, their degradation alters FS-PV-driven functions, such as brain plasticity and memory, and altered PNN structures have been found in neurodevelopmental and central nervous system disorders such as Alzheimer's disease, leading to interest in identifying targets able to modify or participate in PNN metabolism. The serine protease tissue-type plasminogen activator (tPA) plays multifaceted roles in brain pathophysiology. However, its cellular expression profile in the brain remains unclear and a possible role in matrix plasticity through PNN remodeling has never been investigated. RESULT: By combining a GFP reporter approach, immunohistology, electrophysiology, and single-cell RT-PCR, we discovered that cortical FS-PV interneurons are a source of tPA in vivo. We found that mice specifically lacking tPA in FS-PV interneurons display denser PNNs in the somatosensory cortex, suggesting a role for tPA from FS-PV interneurons in PNN remodeling. In vitro analyses in primary cultures of mouse interneurons also showed that tPA converts plasminogen into active plasmin, which in turn, directly degrades aggrecan, a major structural chondroitin sulfate proteoglycan (CSPG) in PNNs. CONCLUSIONS: We demonstrate that tPA released from FS-PV interneurons in the central nervous system reduces PNN density through CSPG degradation. The discovery of this tPA-dependent PNN remodeling opens interesting insights into the control of brain plasticity.


Subject(s)
Parvalbumins , Tissue Plasminogen Activator , Aggrecans/metabolism , Animals , Chondroitin Sulfate Proteoglycans/metabolism , Extracellular Matrix/metabolism , Fibrinolysin/metabolism , Interneurons/physiology , Mice , Parvalbumins/metabolism , Plasminogen/metabolism , Tissue Plasminogen Activator/metabolism
3.
Stroke ; 50(2): 520-523, 2019 02.
Article in English | MEDLINE | ID: mdl-30602353

ABSTRACT

Background and Purpose- Subarachnoid hemorrhage (SAH) is a devastating form of stroke. Oxidative stress contributes to brain injury, but the mechanisms have been poorly studied. Here, we evaluated the role of 12/15-lipoxygenase (12/15-LOX), an enzyme known to cause cell death in ischemic stroke, on brain injury in a mouse model of SAH. Methods- C57Bl6 wild-type mice and Alox15 knockout mice were subjected to SAH using a direct blood injection technique. In SAH wild-type mice, half received the 12/15-LOX inhibitor ML351 and half received vehicle. Immunohistochemistry, brain edema, blood-brain barrier leakage and functional outcomes were assessed 1 and 3 days after SAH induction. Results- SAH led to increased 12/15-LOX in macrophages of the brain parenchyma, adjacent to the subarachnoid blood. Neuronal cell death after SAH was reduced by ML351 and in Alox15 knockout mice. Similarly, SAH induced brain edema, which was 12/15-LOX dependent. Finally, Alox15 gene knockout and inhibitor treatment in wild-type mice with SAH led to an improved behavioral outcome. Conclusions- 12/15-LOX is overexpressed in macrophages after SAH in mice, and inhibition of the 12/15-LOX pathway decreases brain injury and improves neurological outcome. This study suggests 12/15-LOX as a novel therapeutic target to limit brain injury after SAH.


Subject(s)
Arachidonate 12-Lipoxygenase , Arachidonate 15-Lipoxygenase , Brain Injuries , Isoxazoles/pharmacology , Lipoxygenase Inhibitors/pharmacology , Macrophages , Naphthalenes/pharmacology , Oxidative Stress , Subarachnoid Hemorrhage , Animals , Arachidonate 12-Lipoxygenase/genetics , Arachidonate 12-Lipoxygenase/metabolism , Arachidonate 15-Lipoxygenase/genetics , Arachidonate 15-Lipoxygenase/metabolism , Brain Injuries/drug therapy , Brain Injuries/enzymology , Brain Injuries/genetics , Brain Injuries/pathology , Disease Models, Animal , Macrophages/enzymology , Macrophages/pathology , Mice , Mice, Knockout , Oxidative Stress/drug effects , Oxidative Stress/genetics , Subarachnoid Hemorrhage/drug therapy , Subarachnoid Hemorrhage/enzymology , Subarachnoid Hemorrhage/genetics , Subarachnoid Hemorrhage/pathology
4.
Glia ; 65(12): 1961-1975, 2017 12.
Article in English | MEDLINE | ID: mdl-28850711

ABSTRACT

Myelination is a late developmental process regulated by a set of inhibitory and stimulatory factors, including extracellular matrix components. Accordingly, chondroitin sulfate proteoglycans (CSPGs) act as negative regulators of myelination processes. A disintegrin and metalloproteinase with thrombospondin motifs type 4 (ADAMTS-4) is an extracellular protease capable of degrading CSPGs. Although exogenous ADAMTS-4 has been proven to be beneficial in several models of central nervous system (CNS) injuries, the physiological functions of endogenous ADAMTS-4 remain poorly understood. We first used Adamts4/LacZ reporter mice to reveal that ADAMTS-4 is strongly expressed in the CNS, especially in the white matter, with a cellular profile restricted to mature oligodendrocytes. Interestingly, we evidenced an abnormal myelination in Adamts4-/- mice, characterized by a higher diameter of myelinated axons with a shifting g-ratio. Accordingly, lack of ADAMTS-4 is accompanied by motor deficits and disturbed nervous electrical activity. In conclusion, we demonstrate that ADAMTS-4 is a new marker of mature oligodendrocytes contributing to the myelination processes and thus to the control of motor capacities.


Subject(s)
ADAMTS4 Protein/metabolism , Movement Disorders/genetics , Oligodendroglia/metabolism , ADAMTS4 Protein/genetics , Animals , Animals, Newborn , Calcium-Binding Proteins/metabolism , Corpus Callosum/metabolism , Corpus Callosum/pathology , Corpus Callosum/ultrastructure , Disease Models, Animal , Evoked Potentials, Somatosensory/genetics , Evoked Potentials, Somatosensory/physiology , Gait Disorders, Neurologic/etiology , Locomotion/genetics , Locomotion/physiology , Male , Mice , Mice, Transgenic , Microfilament Proteins/metabolism , Microscopy, Electron , Movement Disorders/physiopathology , Myelin Basic Protein/metabolism , Nerve Tissue Proteins/metabolism , Oligodendroglia/pathology , Oligodendroglia/ultrastructure , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Statistics, Nonparametric , beta-Galactosidase/genetics , beta-Galactosidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...